VNRX
$0.19
VolitionRx Limited, a multi-national epigenetics company, develops blood tests to help detect and monitor a range of cancers, and diseases associated with NETosis in the United States, Europe, and Asia.
Recent News
VolitionRx announces automated Nu.Q Vet Cancer Test with Fujifilm Vet Systems
VolitionRx (VNRX) announces the completion of all validation and verification of the chemiluminescent immunoassay version of its Nu.Q Vet Cancer Test with Fujifilm Vet Systems Co. in Japan, allowing use of full automation rather than manual plates in central laboratories. Volition’s supply agreement enables Fujifilm Vet Systems to sell and perform the Nu.Q Vet Cancer Test throughout its network of central reference laboratories in Japan. Claim 70% Off TipRanks PremiumUnlock hedge fund-level data
VolitionRX Ltd (VNRX) Q3 2025 Earnings Call Highlights: Strategic Partnerships and Revenue ...
VolitionRX Ltd (VNRX) reports a 32% revenue increase and strategic agreements, while navigating market unpredictability and capital challenges.
VolitionRX: Q3 Earnings Snapshot
HENDERSON, Nev. AP) — VolitionRX Ltd. (VNRX) on Thursday reported a loss of $5.4 million in its third quarter. The Henderson, Nevada-based company said it had a loss of 5 cents per share.
VolitionRX Ltd (VNRX) Q2 2025 Earnings Call Highlights: Revenue Growth and Strategic Advances ...
VolitionRX Ltd (VNRX) reports a 15% revenue increase and strategic progress in licensing and product commercialization, despite cash flow concerns.
VolitionRX: Q2 Earnings Snapshot
HENDERSON, Nev. AP) — VolitionRX Ltd. (VNRX) on Thursday reported a loss of $6.3 million in its second quarter. On a per-share basis, the Henderson, Nevada-based company said it had a loss of 6 cents.